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Summary
Thrombosis, or complications from thrombosis, currently occupies the top three positions in the
cardiovascular causes of morbidity and mortality in the developed world. There are a limited
number of safe and effective drugs to prevent and treat thrombosis. Animal models of thrombosis
are necessary to better understand the complex components and interactions involved in the
formation of a clot. Tissue factor (TF) is required for the initiation of blood coagulation and likely
plays a key role in both arterial and venous thrombosis. Understanding the role of TF in
thrombosis may permit the development of new antithrombotic drugs. This review will focus on
the role of TF in in vivo models of thrombosis.
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Introduction
Tissue factor (TF) serves as the primary initiator of the coagulation cascade (1–2). It is the
cellular receptor for the plasma factor VII/ VIIa (FVII/VIIa). The TF:FVIIa complex
activates both FIX and FX. Activated FX (FXa), along with its cofactor FVa, is referred to
as the prothombinase complex and cleaves prothrombin to thrombin, which then cleaves
fibrinogen to fibrin. The transglutaminase FXIII then cross-links fibrin which acts to
stabilise the platelet-rich thrombi. The TF:FVIIa complex is inhibited by a multivalent serine
protease inhibitor, known as tissue factor pathway inhibitor (TFPI) (3).
Circulating blood is normally maintained in a fluidic state. The coagulation system is only
activated at sites of vessel injury and this prevents excess blood loss. Following vessel
injury, TF on adventitial cells, such as adventitial fibroblasts, pericytes and smooth muscle
cells (SMCs), activate the clotting system (4–6). Haemostatic clots are localised to the vessel
wall and do not greatly impair blood flow in the vessel. In contrast, thrombotic clots result in
impairment of blood flow and even complete occlusion of the vessel. Thrombotic events
commonly result from a pathologic response to vascular injury, such as atherosclerotic
plaque rupture, the main cause of arterial thrombosis. Vessel wall-derived TF has been
described to provide a “haemostatic envelope” around blood vessels in healthy individuals
(5). In contrast, pathologic expression of TF within the vessel wall or in the blood may
trigger thrombosis.
In addition to TF expression in the vessel wall, there are reports of TF within the blood, so-
called “circulating TF”. Importantly, the level of circulating TF in the blood of healthy
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donors is extremely low and does not appear to contribute to haemostasis (3,7). However,
the level of circulating TF is elevated in various disease states. The relative contribution of
vessel wall vs. circulating TF to thrombosis is currently a highly debated topic. Levels of TF
in the vessel wall are reported to far exceed the amount in blood with an estimated ratio of
1,000:1 (~20 pM vessel wall TF vs. 20 fM circulating) (8–9). Other investigators have
reported higher concentrations of TF in the blood of healthy individuals (10–12) with the
highest levels (37 pM) found in a cohort of arthritis patients (13). This circulating TF is
present at very low levels on monocytes and in the form of small membrane microparticles,
also known as microvesicles (MVs) (14). MVs are derived from activated or apoptotic cells
(15). TF expression can also be induced in blood monocytes and possibly endothelial cells
during pathogenic states, such as sepsis (16–18). Levels of circulating TF are also increased
in chronic pathologic conditions, such as cardiovascular disease, cancer, and sickle cell
disease (19–24).
The role of TF in thrombosis was originally studied using inhibitory drugs in animal models
of thrombosis. More recently, genetic mouse models have been used. However, deletion of
the TF gene was found to be embryonic lethal. (25–27). In order to overcome this lethality,
we generated a “low TF” mouse that express very low levels of human TF from a minigene
(~1% normal levels) in the absence of mouse TF (28). These genetically modified mice,
along with mice containing cell type-specific deletions of the TF gene, have allowed studies
on the relative contribution of vessel wall vs. circulating TF to thrombosis. Additionally,
TFPI heterozygous mice (TFPI+/−) or transgenic overexpression are also a useful tool to
analyse the effects of increasing TF activity (29). The goal of this review is to summarise the
literature on TF inhibition via small molecule inhibitors, blocking antibodies and
recombinant TFPI (rTFPI) on thrombosis in animal models, as well as results from genetic
mouse models.
Arterial thrombosis
Arterial thrombosis is the most common cause of death in the developed world. The primary
cause of arterial thrombosis is either instability or rupture of an atherosclerotic plaque
resulting in localised clot formation and blockage of blood flow with subsequent myocardial
infarction or stroke (Fig. 1A). Arterial thrombi are platelet-rich and are referred to as white
clots. Thrombotic events are most devastating when they occur in the coronary and carotid
arteries, which are prone to atherosclerotic disease. Various risk factors can increase the
incidence of arterial thrombosis, such as smoking, hypertension, hyperlipidaemia, and
diabetes mellitus. TF is present at high concentrations in atherosclerotic plaques in both
cellular and acellular regions (30–32). Furthermore, levels of circulating TF are elevated in
patients with cardiovascular disease, suggesting this source of TF may also contribute to
thrombosis (33–34). This has led to the concept that targeting TF may reduce arterial
thrombosis.
Four types of injury are primarily utilised to initiate arterial thrombosis in animal models.
These consist of the Folts electrical-induction model, the balloon catheter injury model, the
ferric chloride model (FeCl3), and the Rose Bengal laser-induced injury model. All of these
models cause significant injury to the endothelium leading to exposure of blood to TF in the
subendothelial media. The Folts electrical method can be used with or without arterial
occlusion to 50% with a cuff or suture. The resulting positive electrical potential on the
inner surface of the vessel leads to mechanical injury and endothelial cell disruption (35). As
shown in Table 1, inhibition of TF utilising a monoclonal anti-rabbit TF antibody in a rabbit
electrical model prevented thrombus formation in the abdominal aorta and the carotid artery
(36–37). Similarly, an inhibitor of the TF:FVIIa complex (PHA-927) prevented electrical
injury-induced femoral artery thrombosis (38). Furthermore, examination of fibrinolysis in
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electrical stimulation-induced coronary thrombosis demonstrated inhibitors of the TF:FVIIa
complex or downstream inhibition of FXa prevented re-occlusion (39–40). Taken together,
the results indicate that TF initiates thrombosis in the electrical stimulation model.
The balloon catheter injury model is used in larger animals to mimic atherosclerotic plaque
disruption. Expansion of a intraluminal balloon results in disruption of the endothelium (41).
Utilising this model in the coronary artery of pigs and the thoracic aorta of rabbits, two
studies demonstrated that infusion of rTFPI reduced thrombosis (42–43). However, a
TF:FVIIa inhibitor may not be as effective at reducing thrombosis in diseased vasculature,
which contains increased levels of TF. This question was eloquently answered when rabbits
were fed a hyperlipidaemic diet to induce atherosclerotic plaques in the femoral artery.
These plaques were found to contain three times more TF than normal vessels. Mechanical
rupture of the plaques using the balloon catheter injury-induced model of thrombosis was
reduced with a TF:FVIIa inhibitor (44). These results indicate that the balloon catheter
injury and subsequent thrombosis is dependent on TF activity.
The FeCl3 model induces a chemical injury when topically applied to the outer medial/
adventitial artery wall, and is referred to as an outside-in model of injury. FeCl3 reaches the
arterial lumen via an endocytic-exocytic pathway resulting in complete denudation of the
endothelium, the presence of highly reactive oxygen species (ROS), and exposure of the
blood to medial TF resulting in localised thrombosis (45). Thrombosis is monitored by a
reduction in blood flow and time to occlusion of the vessel is used as a quantitative measure
of thrombosis. One of the benefits of this model is that different doses of FeCl3 give
different times of occlusion. This small animal model of thrombosis is thought to be
comparable to arterial thrombosis in large animal models because there are cyclic flow
variations induced by the presence of thrombi in arteries after FeCl3 injury (46). The role of
TF has been examined in this model using mice with either a conditional deletion of the TF
gene in SMC or with increased expression of TFPI in SMCs (29,47). Both studies
demonstrated that a reduction of TF activity was associated with an increase in the time to
occlusion, indicating that “vessel wall” TF mediates FeCl3-induced thrombosis.
The Rose Bengal (tetrachlorotetraiodofluorescein) model of thrombosis is another model of
human arterial thrombosis created by the generation of ROS (48). The Rose Bengal model
utilises a photochemical reaction to cause localised induction of endothelial injury via ROS
formation. Rose Bengal can be injected into the blood (inside-out injury) or is topically
applied (outside-in injury). Exposure of Rose Bengal to a laser (543 nm) induces singlet
oxygen radicals (49). Most studies inject Rose Bengal into the blood via the tail vein.
Thrombosis is then monitored with a flow probe that determines the time to occlusion.
Utilising the low TF mouse model and bone marrow transplantation, Day et al. demonstrated
that TF in the carotid artery vessel wall, and not haematopoietic cell-derived TF, is
responsible for arterial thrombosis (9). This study, together with the aforementioned FeCl3
SMC conditional deletion studies, strongly indicates that circulating TF does not contribute
to arterial thrombosis in healthy mice. Another study with TFPI+/− mice, which have
increased levels of TF activity, demonstrated a faster time to occlusion compared to TFPI+/+
mice when carotid atherosclerotic plaques were disrupted utilising Rose Bengal(50).
Venous thrombosis
Venous thromboembolism (VTE), which is a collective term for both deep-vein thrombosis
(DVT) and pulmonary embolism (PE), is the third leading cause of cardiovascular death in
the developed world. Commonly formed in the large veins of the leg, these clots are
primarily composed of red cells and fibrin (known as red clots) (Fig. 1B). A common
complication of venous thrombosis is PE, which occurs when part of the thrombus breaks
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away and travels to the lung resulting in partial or complete cessation of blood flow in the
pulmonary artery. As opposed to arterial thrombosis, which occurs due to arterial injury and
exposure of the sub-endothelium, venous thrombosis mainly occurs due to changes in the
composition of the blood, changes in blood flow and/or activation of the endothelium (51–
52). Many different factors can increase the incidence of VTE, such as the presence of
cancer, obesity, and major surgery (53–54). Thrombophilia is the propensity to develop
thrombosis as a result of changes in the blood itself. This can result from an increase in
levels of circulating clotting factors, a resistance of clotting factors to inactivation (i.e. factor
V Leiden), or a decrease in levels of anticoagulants.
While arterial thrombosis is caused by TF-derived from the vessel wall or within a rupture
plaque, venous thrombosis occurs in the absence of gross vein wall disruption (55). It has
been suggested that increased levels of circulating TF may trigger venous thrombus
formation (56–57). Furthermore, mononuclear cell-associated TF is elevated 24 and 48
hours postoperatively and precedes clinical occurrence of VTE, strongly suggesting a
positive association between surgery-induced TF expression and VTE (58). Interestingly,
monocytes from patients with VTE had increased levels of TF antigen and activity
compared with controls (59–61). In addition, TF antigen has been detected in human deep-
vein thrombi (62). These data suggest that TF is present in venous thrombi and that it may
play a key role in initiating venous thrombosis.
Two methods of inducing venous thrombosis are utilised in animal models (Table 2). These
are the inferior vena cava (IVC) ligation/ stasis model and the collagen-coated thread
technique. Although several studies have also utilised Rose Bengal and FeCl3 of veins, these
are not widely accepted as good models due to their non-physiological ablation of the
endothelium. The most commonly used model is ligation of the IVC, which results in stasis
of the blood and formation of thrombi (63–64). A recent study by Zhou et al. using a rat IVC
ligation model found TF staining in monocytes within the thrombi and endothelial cell
adjacent to the thrombi (65). Szaloney et al. demonstrated that TF blockage with an inhibitor
of the TF:FVIIa complex (PHA-796) reduced thrombosis in the IVC ligation model in non-
human primates (66). In a translational study, Biro et al. demonstrated that MVs from
cardiac surgery patients increased thrombosis in a rat model of IVC ligation (67). This effect
was abolished when the MVs were preincubated with an anti-human TF antibody,
demonstrating MVs promote venous thrombosis in a TF-dependent manner. Day and
colleagues confirmed the role of TF in venous thrombosis by showing that low TF mice
have smaller thrombi than controls in an IVC ligation model (9). However, they found that
decreasing the level of TF expression in haematopoietic cells did not affect thrombosis in
this model. Nevertheless, a reduction of TF activity either via use of an inhibitory drug,
genetic manipulation, or inhibitory antibody reduced venous thrombosis in these animal
models.
The collagen-coated thread technique has been utilised as a model of venous thrombosis in
rabbits. The procedure consists of interrupting blood flow to the jugular vein, and either
inserting a cotton thread pre-soaked in 1 mg/ml fibrillar collagen, and then restoring blood
flow, or inserting a silicon catheter with the pre-soaked cotton thread attached to the lumen
(68). Himber et al. demonstrated that a monoclonal antibody to rabbit TF inhibited fibrin
accumulation and thrombus propagation in this model of venous thrombosis (68). Further,
they demonstrated that leukocytes stained for TF within the thrombi. Further studies are
needed to determine the cellular source(s) of TF responsible for initiating venous
thrombosis.
While these models allow the analysis of pathways that contribute to venous thrombosis in
animals, they both have limitations with regard to the formation of venous thrombi. The IVC
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ligation model has been criticised because this procedure may injure the vasculature during
suture positioning, thus possibly releasing vessel wall TF into the blood. Further, the IVC
ligation model stops all venous blood flow, which will reduce the delivery of MVs. In
contrast, most venous thrombi occur in regions of disturbed or reduced flow. While the
collagen-coated thread model has blood flow, the process of introducing the thread via
clamping and insertion of a surgical graft, may also introduce vessel wall TF into the
circulation. A new model of venous thrombosis is gaining popularity and is thought to be
more physiologically relevant. Known as the St. Thomas’ Model of venous thrombosis, a
stenotic reduction of blood flow (~80–90%) in the IVC is produced by a silk ligature, and
then a clamp is used to damage the endothelium (69). This model of stenosis allows for
delivery of leukocytes and MVs to the site of thrombosis to a greater extent than the ligation
model. Kollnberger et al. demonstrated that mice lacking the TF gene in myeloid cells had a
dramatic reduction in venous thrombus size when compared to controls when utilizing this
stenosis model (70). This study demonstrates that IVC thrombosis is also dependent upon
TF.
Microvascular thrombosis
Microvascular thrombosis examines clot formation in small cre-master or mesenteric
arterioles of mice. Specifically, a laser is focused through an optical port of a microscope
onto the target vessel. The laser beam is focused so that the resultant heat injury is only
induced in a particular part of the vessel. Utilising this laser technology can physically injure
a single or multiple endothelial cells with minimal damage to cells in the vessel wall. The
thrombus is then observed by intravital microscopy to view the accumulation of TF, fibrin,
and platelets. This model of thrombus formation has some advantages over the
aforementioned arterial and venous models. The procedure is minimally invasive and
requires minimal animal handling or perturbation. Furthermore, the injuries induced are
small in size and multiple injuries can be produced in one mouse (71). However, the
disadvantages of this model are the use of non-physiologic heat injury and the very small
size of the vessels that may not mimic thrombosis in human coronary and carotid arteries.
Furie et al. have demonstrated that MVs from the blood rapidly accumulate into the
thrombus. This is due to an interaction between P-selectin glycoprotein ligand 1 on the MV
and P-selectin on the surface of the activated platelet. Accumulation of TF precedes fibrin
formation within the thrombus (72–73). Recently, Chou et al. demonstrated that both vessel
wall and haematopoietic cell-derived TF-positive MVs contributed to thrombosis in this
model (Table 2) (74). Furthermore, additional studies demonstrated that circulating TF is
specifically delivered via MVs (75). These data demonstrate that both vessel wall TF and
haematopoietic cell-derived TF-positive MVs contribute to formation of a thrombus in the
model of laser-injured microvasculature.
Disseminated intravascular coagulation
Disseminated intravascular coagulation (DIC) is characterised by microvascular thrombosis
(76). Sepsis and endotoxaemia are the most common pathologic conditions leading to DIC
(77–78). DIC can also be caused by severe trauma, such as surgery, resulting in the release
of “tissue debris” into the circulation and subsequent activation of coagulation (79–81).
After introduction of endotoxin or live Gram-negative bacteria into experimental animals,
thrombin generation is increased after a period of 3–5 hours (82). Originally it was thought
that the contact system, comprised of FXI, FXII, and plasma kallikrein, mediated DIC-
induced thrombosis. However, studies have demonstrated that these proteins were not
activated in sepsis (83–84). Further experiments demonstrated that induction of TF
expression and subsequent generation of thrombin was the mechanism of DIC-induced
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thrombosis. Most human patients diagnosed with DIC have detectable levels of TF antigen
in their plasma (85). Moreover, sepsis induces the expression of TF by vascular cells, such
as monocytes (86).
There are numerous studies that have examined the role of TF in DIC (Table 3). A
monoclonal TF antibody (87), rTFPI (88), and FVIIa inhibitor (89) were all shown to reduce
DIC and death in a lethal baboon model of sepsis. Furthermore, chimpanzees pre-injected
with a monoclonal anti-TF antibody (90) or a monoclonal antibody to FVII/FVIIa (91) were
also protected from endotoxin-induced coagulation. Similar results were found in a rabbit
model of DIC, where a polyclonal rabbit TF inhibited activation of coagulation in animals
injected with endotoxin (92). Recently, we found that low TF mice had reduced levels of
thrombin-anti-thrombin (TAT) in a mouse model of endotoxaemia (93). Moreover, this
study also demonstrated that haematopoietic-derived TF played a role in the activation of
coagulation in endotoxaemic mice. Our recent studies indicate that TF expressed by both
haematopoietic cells and non-haematopoietic cells contributes to activation of coagulation in
endotoxaemic mice (94). Monocytes were the major haematopoietic cell that expressed TF.
However, deletion of TF in endothelial cells did not reduce the activation of coagulation
indicating that TF expression by other non-haematopoietic cells drives thrombosis in this
model. In sum, these studies demonstrate TF plays a central role in DIC induced by
endotoxaemia and sepsis.
Conclusion
In conclusion, all of the aforementioned models of arterial, venous, and microvascular
thrombosis, as well as DIC, are all dependent on TF for initiating thrombosis. Models of
arterial thrombosis induce vessel wall injury, similar to atherosclerotic plaque rupture, and
are primarily dependent on vessel-wall derived TF for initiation of the coagulation cascade.
Other studies indicate that circulating TF contributes to venous thrombosis and
microvascular thrombosis. Finally, both haematopoietic and non-haematopoietic cell-
derived TF activate coagulation in a mouse model of endotoxaemia. Further work is needed
to elucidate the different cell types that express TF and their role in different models of
thrombosis. Mice with cell type-specific deletion of the TF gene may be able to answer
some of these questions.
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Figure 1. Models showing the cellular sources of TF that contributes to arterial and venous
thrombosis
A) Arterial thrombosis. The primary trigger of arterial thrombosis in a diseased vessel is the
rupture of an atherosclerotic plaque. This involves disruption of the fibrous SMC cap
exposing blood to TF in the plaque. The resultant clot is mainly composed of platelets with
lower levels of cross-linking fibrin, and is referred to as a “white clot”. B) Venous
thrombosis. Venous thrombosis occurs on a relatively undisturbed endothelial layer. Venous
thrombosis may be triggered by circulating TF associated with MVs. The clot is mainly
composed of fibrin with platelets and trapped red blood cells and is referred to as a “red
clot”.
Owens and Mackman Page 12
Thromb Haemost. Author manuscript; available in PMC 2011 February 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Owens and Mackman Page 13
Ta
bl
e 
1
R
ol
e 
of
 ti
ss
ue
 fa
ct
or
 (T
F)
 in
 a
rte
ria
l t
hr
om
bo
si
s m
od
el
s.
In
ju
ry
V
as
cu
la
r 
lo
ca
tio
n
A
ni
m
al
 sp
ec
ie
s
In
hi
bi
to
r/
ge
ne
T
F 
de
pe
nd
en
t
St
ud
y 
de
sc
ri
pt
io
n
R
ef
er
en
ce
El
ec
tri
ca
l s
tim
ul
at
io
n
C
ar
ot
id
 a
rte
ry
R
ab
bi
t
m
ab
 ra
bb
it 
TF
Y
es
Th
ro
m
bo
si
s w
as
 si
gn
ifi
ca
nt
ly
 a
tte
nu
at
ed
 in
 a
ll 
ni
ne
 ra
bb
its
 te
st
ed
37
El
ec
tri
ca
l s
tim
ul
at
io
n
A
bd
om
in
al
 a
or
ta
R
ab
bi
t
m
ab
 ra
bb
it 
TF
Y
es
Pr
ev
en
te
d 
pr
oc
oa
gu
la
nt
 a
ct
iv
ity
 in
 c
irc
ul
at
in
g 
bl
oo
d
36
El
ec
tri
ca
l s
tim
ul
at
io
n
Fe
m
or
al
 a
rte
ry
N
-H
 p
rim
at
e
PH
A
-9
27
Y
es
Pr
ev
en
te
d 
th
ro
m
bu
s-
in
du
ce
d 
ve
ss
el
 o
cc
lu
si
on
 w
ith
 li
ttl
e 
im
pa
ct
 o
n
bl
ee
di
ng
38
B
al
lo
on
 c
at
he
te
r i
nj
ur
y
Th
or
ac
ic
 a
or
ta
R
ab
bi
t
rh
TF
PI
Y
es
B
ol
us
 in
fu
si
on
 o
f r
TF
PI
 in
hi
bi
te
d 
fib
rin
 fo
rm
at
io
n 
an
d 
ne
oi
nt
im
al
de
ve
lo
pm
en
t
42
B
al
lo
on
 c
at
he
te
r i
nj
ur
y
C
or
on
ar
y 
ar
te
ry
Pi
g
rh
TF
PI
Y
es
R
ed
uc
ed
 a
cu
te
 th
ro
m
bo
si
s a
nd
 in
tim
al
 h
yp
er
pl
as
ia
 a
fte
r a
ng
io
pl
as
ty
43
B
al
lo
on
 c
at
he
te
r i
nj
ur
y
Fe
m
or
al
 a
rte
ry
R
ab
bi
t
FV
II
ai
Y
es
D
os
e-
de
pe
nd
en
tly
 re
du
ce
d 
th
ro
m
bu
s f
or
m
at
io
n
44
Fe
rr
ic
 c
hl
or
id
e
C
ar
ot
id
 a
rte
ry
M
ou
se
SM
C
 C
re
 T
FP
I F
lo
x
de
le
tio
n
Y
es
A
tte
nu
at
io
n 
of
 a
rte
ria
l t
hr
om
bo
si
s w
ith
ou
t s
ys
te
m
ic
 si
de
-e
ff
ec
ts
29
Fe
rr
ic
 c
hl
or
id
e
C
ar
ot
id
 a
rte
ry
M
ou
se
SM
C
 C
re
 T
F 
Fl
ox
de
le
tio
n
Y
es
C
on
di
tio
na
l d
el
et
io
n 
of
 S
M
C
 T
F 
re
su
lte
d 
in
 a
 m
ar
ke
d 
re
du
ct
io
n 
of
th
ro
m
bo
si
s
47
R
os
e 
B
en
ga
l
C
ar
ot
id
 a
rte
ry
M
ou
se
TF
PI
+/
−
Y
es
TF
PI
+/
−
 a
ug
m
en
te
d 
th
ro
m
bo
si
s s
ug
ge
st
in
g 
TF
PI
 in
hi
bi
tio
n 
of
 T
F
at
te
nu
at
es
 c
oa
gu
la
tio
n
50
R
os
e 
B
en
ga
l
C
ar
ot
id
 a
rte
ry
M
ou
se
Lo
w
 T
F 
ge
ne
Y
es
Lo
w
 T
F 
m
ic
e 
w
er
e 
pr
ot
ec
te
d 
fr
om
 c
ar
ot
id
 th
ro
m
bo
si
s
9
A
bb
re
vi
at
io
ns
: N
-H
: n
on
-h
um
an
; m
ab
: m
on
oc
lo
na
l a
nt
ib
od
y;
 P
H
A
-9
27
: T
F:
FV
II
 c
om
pl
ex
 in
hi
bi
to
r; 
rh
: r
ec
om
bi
na
nt
 h
um
an
.
Thromb Haemost. Author manuscript; available in PMC 2011 February 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Owens and Mackman Page 14
Ta
bl
e 
2
R
ol
e 
of
 ti
ss
ue
 fa
ct
or
 (T
F)
 in
 v
en
ou
s a
nd
 m
ic
ro
va
sc
ul
ar
 th
ro
m
bo
si
s m
od
el
s.
T
hr
om
bo
tic
 m
et
ho
d
V
as
cu
la
r 
lo
ca
tio
n
A
ni
m
al
 sp
ec
ie
s
In
hi
bi
to
r/
ge
ne
T
F 
de
pe
nd
en
t
St
ud
y 
de
sc
ri
pt
io
n
R
ef
er
en
ce
Li
ga
tio
n
IV
C
N
-H
 P
rim
at
e
PH
A
-7
96
Y
es
Th
ro
m
bo
si
s w
as
 in
hi
bi
te
d 
in
 a
 d
os
e-
de
pe
nd
en
t m
an
ne
r
66
Li
ga
tio
n
IV
C
R
at
an
ti-
TF
 A
b
Y
es
In
hi
bi
tio
n 
of
 T
F 
ab
ol
is
he
d 
th
ro
m
bo
si
s f
ro
m
 M
V
s c
ol
le
ct
ed
 fr
om
 c
ar
di
ac
su
rg
er
y 
pa
tie
nt
s
67
Li
ga
tio
n
IV
C
M
ou
se
Lo
w
 T
F 
ge
ne
Y
es
Lo
w
 T
F 
m
ic
e 
w
er
e 
pr
ot
ec
te
d 
fr
om
 v
en
ou
s t
hr
om
bo
si
s
9
C
ol
la
ge
n-
co
at
ed
 th
re
ad
Ju
gu
la
r V
ei
n
R
ab
bi
t
an
ti-
TF
 A
b
Y
es
In
hi
bi
tio
n 
of
 T
F 
si
gn
ifi
ca
nt
ly
 d
ow
nr
eg
ul
at
es
 fi
br
in
 a
cc
um
ul
at
io
n
68
La
se
r i
nj
ur
y
C
re
m
as
te
r a
rte
rio
le
s
M
ou
se
Lo
w
 T
F 
ge
ne
Y
es
In
hi
bi
tio
n 
of
 th
ro
m
bu
s f
or
m
at
io
n 
di
sp
la
yi
ng
 sm
al
l p
la
te
le
t t
hr
om
bi
 la
ck
in
g 
TF
or
 fi
br
in
74
La
se
r i
nj
ur
y
C
re
m
as
te
r a
rte
rio
le
s
M
ou
se
Lo
w
 T
F 
ge
ne
Y
es
TF
-b
ea
rin
g 
M
V
s d
er
iv
ed
 fr
om
 h
ae
m
at
op
oi
et
ic
 c
el
ls
 in
iti
at
e 
th
ro
m
bu
s f
or
m
at
io
n
75
A
bb
re
vi
at
io
ns
: N
-H
: n
on
-h
um
an
; A
b:
 a
nt
ib
od
y;
 P
H
A
-9
27
: T
F:
FV
II
 c
om
pl
ex
 in
hi
bi
to
r
Thromb Haemost. Author manuscript; available in PMC 2011 February 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Owens and Mackman Page 15
Ta
bl
e 
3
R
ol
e 
of
 ti
ss
ue
 fa
ct
or
 (T
F)
 in
 m
od
el
s o
f d
is
se
m
in
at
ed
 in
tra
va
sc
ul
ar
 c
oa
gu
la
tio
n 
(D
IC
).
T
hr
om
bo
tic
 m
et
ho
d
V
as
cu
la
r 
lo
ca
tio
n
A
ni
m
al
 sp
ec
ie
s
In
hi
bi
to
r/
ge
ne
T
F 
de
pe
nd
en
t
St
ud
y 
de
sc
ri
pt
io
n
R
ef
er
en
ce
En
do
to
xi
n 
or
 T
F 
In
je
ct
io
n
B
lo
od
 a
na
ly
si
s
R
ab
bi
t
Po
ly
cl
on
al
 ra
bb
it 
TF
 A
b
Y
es
D
IC
 w
as
 a
tte
nu
at
ed
, h
ow
ev
er
, e
nd
ot
ox
ic
 sh
oc
k 
re
m
ai
ne
d
un
ch
an
ge
d
92
En
do
to
xi
n 
in
je
ct
io
n
B
lo
od
 a
na
ly
si
s
B
ab
oo
ns
m
A
b 
TF
Y
es
Pr
ot
ec
te
d 
ag
ai
ns
t D
IC
 a
ct
iv
at
io
n 
of
 c
oa
gu
la
tio
n
87
En
do
to
xi
n 
in
je
ct
io
n
B
lo
od
 a
na
ly
si
s
B
ab
oo
ns
rT
FP
I
Y
es
A
ct
iv
at
io
n 
of
 c
oa
gu
la
tio
n,
 m
ea
su
re
d 
by
 T
A
T,
 in
hi
bi
te
d 
an
d
de
cr
ea
se
d 
IL
-6
88
En
do
to
xi
n 
in
je
ct
io
n
B
lo
od
 a
na
ly
si
s
B
ab
oo
ns
FV
II
ai
Y
es
A
ct
iv
at
io
n 
of
 c
oa
gu
la
tio
n 
in
hi
bi
te
d,
 a
s w
el
l a
s I
L-
6 
an
d 
IL
-8
, b
ut
no
t T
N
F-
α
89
En
do
to
xi
n 
in
je
ct
io
n
B
lo
od
 a
na
ly
si
s
C
hi
m
ps
m
A
b 
TF
Y
es
A
ct
iv
at
io
n 
of
 c
oa
gu
la
tio
n 
in
hi
bi
te
d,
 b
ut
 n
o 
ef
fe
ct
 o
n 
IL
-6
 o
r T
N
F-
α
cy
to
ki
ne
s
90
En
do
to
xi
n 
in
je
ct
io
n
B
lo
od
 a
na
ly
si
s
C
hi
m
ps
m
A
b 
FV
II
/F
V
II
a
Y
es
D
IC
-in
du
ce
d 
co
ag
ul
at
io
n 
in
hi
bi
te
d
91
En
do
to
xi
n 
in
je
ct
io
n
B
lo
od
 a
na
ly
si
s
M
ou
se
Lo
w
 T
F 
G
en
e
Y
es
Lo
w
 T
F 
m
ic
e 
ar
e 
pr
ot
ec
te
d 
fr
om
 e
nd
ot
ox
ae
m
ia
 a
ct
iv
at
io
n 
of
co
ag
ul
at
io
n
93
En
do
to
xi
n 
in
je
ct
io
n
B
lo
od
 a
na
ly
si
s
M
ou
se
Ly
sM
 a
nd
 T
ie
2 
C
re
 T
F
Fl
ox
 d
el
et
io
n
Y
es
C
on
di
tio
na
l d
el
et
io
n 
of
 m
ye
lo
id
 T
F 
pr
ot
ec
ts
 a
ga
in
st
 e
nd
ot
ox
ae
m
ia
-
in
du
ce
d 
co
ag
ul
at
io
n
94
A
bb
re
vi
at
io
ns
: m
ab
: m
on
oc
lo
na
l a
nt
ib
od
y;
 F
V
II
ai
: a
ct
iv
e 
si
te
 in
hi
bi
to
r o
f F
V
II
; r
: r
ec
om
bi
na
nt
Thromb Haemost. Author manuscript; available in PMC 2011 February 23.
